Supported by an educational grant from Novartis Pharmaceuticals Corporation.
Cardiovascular (CV) disease, specifically coronary heart disease, represents a significant healthcare burden. An improved understanding of the atherothrombotic processes has led to the identification of biomarkers associated with increased CV risk, such as low-density lipoprotein cholesterol and high-sensitivity C-reactive protein, a biomarker for inflammation. In order to address the need to reduce CV events among patients at an increased vascular risk due to elevated levels of C-reactive protein, trials are being conducted to investigate the effect of targeting inflammation to reduce CV risk. Improving knowledge of the role of vascular inflammation (VI) in mediating atherothrombosis will provide the foundation to assess the most recent clinical evidence on the correlation between inflammation and atherothrombosis and the rationale to target inflammatory pathways.
This educational initiative has been designed for cardiologists, internal medicine physicians, and other healthcare providers involved in the care of patients with VI.
Upon completion of this educational activity, participants should be able to:
Discuss the inflammatory processes that contribute to atherothrombosis
Recognize the need to target inflammation for the prevention of atherothrombosis
Evaluate data from clinical trials targeting VI to reduce recurrence of CV events
Identify patients with heart disease that will benefit from anti-inflammatory therapy
Conflict Of Interest Disclosure Policy
Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty/planners reported their financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity under the Faculty heading below.
Paul M. Ridker, MD, MPH, FACC Director, Center for Cardiovascular Disease Prevention Brigham and Women’s Hospital Eugene Braunwald Professor of Medicine Harvard Medical School Boston, MA
Dr. Ridker discloses the following: Consulting fees: AstraZeneca, Quintiles, Sanofi, TEVA Contracted research: American Heart Association, Amgen, AstraZeneca, Donald W. Reynolds Foundation, Doris Duke Charitable Foundation, James and Polly Annenberg La Vea Charitable Trusts, Kowa Pharmaceuticals, Leducq Foundation, National Cancer Institute, National Heart, Lung, and Blood Institute, Novartis Pharmaceuticals Corporation, Pfizer Patent holder: Co-inventor on patents held by Brigham and Women’s Hospital and licensed to AstraZeneca and Siemens
Brendan M. Everett, MD, MPH Director, General Cardiology Inpatient Service Brigham and Women’s Hospital Assistant Professor of Medicine Harvard Medical School Boston, MA
Dr. Everett discloses the following: Consulting fees: Novartis Pharmaceuticals Corporation, Roche Diagnostics Contracted research: Kowa Pharmaceuticals, National Heart, Lung, and Blood Institute, Novartis Pharmaceuticals Corporation
Accredited Provider Disclosure
Patima Tanapat, PhD, has no real or apparent conflicts of interest to disclose.
AMA PRA Category 1 Credit(s)TM
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.
Integrity Continuing Education designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Novartis Pharmaceuticals Corporation do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Integrity Continuing Education, Inc. and Novartis Pharmaceuticals Corporation. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.
There are no fees for participating and receiving CME credit for this activity. During the period of January 26, 2018 through January 26, 2019, participants must:
Read the learning objectives and faculty disclosures
Complete the pre-test
Study the educational activity
Complete the post-test and the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed post-test with a score of 70% or higher.
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or email@example.com.